Navigation Links
Trubion Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
Date:9/8/2009

SEATTLE, Sept. 8 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that executives will present a corporate update at the upcoming Morgan Stanley Global Healthcare Conference in New York City. Peter Thompson, M.D., FACP, president, chief executive officer and chairman of the board of directors, and Michelle Burris, senior vice president and chief financial officer, are scheduled to present on Monday, Sept. 14 at 8 a.m. EDT. The presentation will be available via audio webcast at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TRBN&item_id=2400648.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies dev
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
4. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
5. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
6. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
7. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
8. Trubion Announces Presentations at Upcoming Investor Conferences
9. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
10. Trubion Announces Presentations at Upcoming Investor Conferences
11. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the ... a company overview at the Nomura Biotechnology Conference on Thursday, ... Boston, MA. A live webcast of ... section of the Company,s website, www.isispharm.com .  A replay ... and will be archived for a limited time. ...
(Date:10/30/2014)... challenges in the development of quantum technologies has been ... paper published today (28 October) in Nature Communications ... make a new type of flexibly designed microscopic trap ... sensors and specialised superfast computers, often depend on harnessing ... trapping these tiny particles are hugely problematic because of ...
(Date:10/27/2014)... The new research report, “Gas ... Medium), Sub-type (Primary & Secondary), and End-User (Transmission ... & Power Generation) - Trends and Forecasts to ... analysis and forecasting of the market size. , ... 52 Figures spread through 146 Pages and in-depth ...
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information ... recent Ebola concern in the United States ... virus.  The healthcare market researcher said the FDA,s Emergency Use ... vitro diagnostic tests for the detection of the Ebola ... proved useful.  Kalorama routinely assess the IVD industry and ...
Breaking Biology Technology:Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3
... October 6, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... tiaras to anklets are treasures but these gemstones inside ... Reserve University researchers are building implants made of diamond ... and electrical changes in the brain of patients suffering ... movement in the paralyzed. The work of Heidi ...
... Oct. 4 issue of the high-impact journal, Applied ... the University of Cincinnati and start-up company Gamma Dynamics ... electronic devices. This patent-pending electrofluidics breakthrough by the ... partner companies Gamma Dynamics, Dupont and Sun Chemical follows ...
Cached Biology Technology:Elsevier Introduces Article-Based Publishing to Increase Publication Speed 2Elsevier Introduces Article-Based Publishing to Increase Publication Speed 3Elsevier Introduces Article-Based Publishing to Increase Publication Speed 4Elsevier Introduces Article-Based Publishing to Increase Publication Speed 5Elsevier Introduces Article-Based Publishing to Increase Publication Speed 6Elsevier Introduces Article-Based Publishing to Increase Publication Speed 7Elsevier Introduces Article-Based Publishing to Increase Publication Speed 8Gem of an idea: A flexible diamond-studded electrode implanted for life 2Gem of an idea: A flexible diamond-studded electrode implanted for life 3Breakthrough e-display means electronics with high speed, high readability and low power usage 2Breakthrough e-display means electronics with high speed, high readability and low power usage 3Breakthrough e-display means electronics with high speed, high readability and low power usage 4
(Date:10/31/2014)... steps involved in programmed cell death, offering new targets ... neurodegenerative diseases. , The research teams from the ... the three-dimensional structure of a key cell death protein ... it causes cell death. Their studies were published in ... Proceedings of the National Academy of Sciences . ...
(Date:10/31/2014)... 2014  HITLAB SM , a healthcare innovation ... inaugural HITLAB Innovators Summit SM on December ... will partner with the Clinton Foundation,s Health Matters ... Columbia Business School Alumni Club of ... and Operations Research, bringing together leaders in healthcare ...
(Date:10/30/2014)... When most animals begin life, cells immediately begin accepting ... organ. However, mammals, including humans, are special. The cells ... choice – to become the protective placenta or to ... critical first step that research from Michigan State University ... current issue of PLOS Genetics , ...
Breaking Biology News(10 mins):A matter of life and death: Cell death proteins key to fighting disease 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3Identifying the source of stem cells 2
... from brake linings and mining operations can affect salmon ... a Washington State University researcher. Jenifer McIntyre found the ... they won,t detect a compound that ordinarily alerts them ... is not getting the information it needs to make ...
... Switzerland. Research to be presented at the Annual Meeting of ... foremost society for research into all aspects of eating and ... reduces the quality of sleep in rats. Using radio-telemetry, ... consumed a high fat diet for 8 weeks. Compared to ...
... debilitating illnesses one can develop. Currently, the disease afflicts 6.5 ... to between 11 and 16 million, or 1 in 85 ... one to grow forgetful, confused and, eventually, catatonic. Recently approved ... consensus on the underlying mechanism of the disease. "We ...
Cached Biology News:Copper making salmon prone to predators 2Small molecule may play big role in Alzheimer's disease 2Small molecule may play big role in Alzheimer's disease 3Small molecule may play big role in Alzheimer's disease 4
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: